Dyadic receives $3.1M Gates Foundation grant for RSV and malaria mAb development

DYADIC INTERNATIONAL INC

Grant of $3,092,136 from Bill & Melinda Gates Foundation for monoclonal antibody development using C1 platform.
Targets RSV (100K+ deaths annually, 99% in LMICs) and malaria (249M cases, 608K deaths in 2022).
Aims to reduce production costs and improve global access to affordable therapeutics for underserved populations.
Dyadic plans to commercialize resulting antibodies via licensure if development succeeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.